MBX-8025 yields ‘striking’ efficacy results but new safety signal in primary biliary cholangitisNovember 11, 2016AASLDHepatitis
Cenicriviroc was well-tolerated but did not outperform placebo across all endpointsNovember 11, 2016AASLD
